Kornimate/medical-research-clean huggingface dataset:
hepatocyte transplantation in liver failure

Conditions: Liver Failure

Summary: the investigators research will examine the safety and efficacy of hepatocyte transplantation in the patient with acute liver failure without history of chronic disease. the investigators will study the effectiveness in providing a bridge of support for patient survival until whole organ transplantation is possible. this support may also be a bridge to recovery; by allowing the native liver to recover so that orthotopic liver transplant is not necessary. the investigators will also study the safety and efficacy of hepatocyte transplantation in the patient with chronic liver disease. underlying etiologies of chronic disease may arise from cirrhosis, fibrosis or inherited metabolic disorders. the investigators will examine cell transplantation in end-stage patients not eligible for whole organ transplant. these patients may benefit with an amelioration of symptoms that will allow other therapeutic treatments. the investigators study will also examine the ability of transplanted hepatocytes to treat inherited metabolic diseases (ex., crigler-najjar disease, familial hypercholesterolemia, urea cycle disorders). cell transplant may also act as a 'bridge' to whole organ transplant or improve function, permitting easier disease control through traditional therapy.


Eligibility criteria:
inclusion criteria: * inclusion criteria are specific to the classification of liver disease, i.e., fulminant or non-fulminant or metabolic disease exclusion criteria: * any systemic infection * unstable coronary artery disease * hiv infection * preformed antibodies to class antigens that are present on all available donor samples (only cells from an abo-compatible donor with no hla class i antigen to which the recipient has preformed antibodies will be selected for transplant.) * hepatopulmonary disease (room air pa02 ≤ 60 mmhg) * testing positive for hepatitis b surface antigen (hbsag), hepatitis be antigen (hbeag) or hepatitis b virus by dna and unable to receive or pay for hepatitis b treatment. * any current or anticipated contraindication for the use of tacrolimus and cyclosporine, methylprednisolone or prednisone. * female patients who are breast feeding * any medical condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this trial.

Keywords: liver failure hepatocyte transplantation liver transplantation
efficacy and safety of levamisole combined with standard prednisolone in warm antibody autoimmune hemolytic anemia.

Conditions: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Hemolysis; Hematologic Diseases; Autoimmune Diseases; Immune System Diseases; Pathologic Processes

Summary: the purpose of this study is to determine whether levamisole plus prednisone can further improve the efficacy，extend the remission duration and reduce the dosage of prednisone for newly diagnosed warm antibody autoimmune hemolytic anemia.

the first line treatment in warm antibody autoimmune hemolytic anemia (waiha) is the glucocorticoid, but most of the patients, hemolytic events will frequently recurred after end of treatment or during the gradual reduction in dosage of prednisolone. as a result, many patients will finally accepted long-term glucocorticoids or other immunosuppressive drugs. how to reduce the relapse rate of aiha is still difficult. levamisole（lms）is a immunoregulator.recent studies have shown lms has been widely used to treat autoimmune diseases ,such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. the purpose of this study is to determine whether lms combined with prednisolone can further improve the efficacy，extend the remission duration and reduce the dosage of prednisone for newly diagnosed warm antibody autoimmune hemolytic anemia.

Eligibility criteria:
inclusion criteria: * clinical and biochemical signs of hemolytic anaemia * positive coombs test with anti-igg or and with anti-cd3d * newly diagnosed warm autoimmune hemolytic anemia * adequate contraceptive measures for women of childbearing potential * informed consent signed exclusion criteria: * active infection which requires antibiotic treatment * pregnant or lactating women * epilepsy and mental illness * kidney and liver function abnormal

Keywords: autoimmune hemolytic anemia hemolytic anemia levamisole treatment of autoimmune hemolytic anemia warm antibody dependant autoimmune hemolytic anemia
prospective clinical follow-up of the echo bi-metric microplasty stem for total hip arthroplasty

Conditions: Hip Osteoarthritis

Summary: the primary objective of this study is to characterize survivorship of the echo bi-metric microplasty stem in unilateral or bilateral primary total hip arthroplasty at 5 years postoperative.

primary objective the primary objective of this study is to characterize survivorship of the echo bi-metric microplasty stem in unilateral or bilateral primary total hip arthroplasty at 5 years postoperative. secondary objectives safety will be evaluated by monitoring the frequency and incidence of adverse events over time to 10 years postoperative. clinical, functional, radiographic, and quality of life outcomes will be assessed over time to 7 years postoperative. clinical outcomes will be measured using the harris hip score and physical exam form. radiographs will be reviewed to assess alignment, radiolucencies and other radiographic parameters. health status and functional ability will be measured using the eq-5d-3l and the ucla activity score.

Eligibility criteria:
inclusion criteria: * subjects are eligible for this trial if they satisfy all of the following criteria: * patient is 18 to 65 years of age, inclusive * patient is skeletally mature * patient qualifies for primary unilateral or bilateral total hip arthroplasty based on physical exam and medical history including at least one of the following: * osteoarthritis * avascular necrosis * rheumatoid arthritis * correction of functional deformity * treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques * patient has no history of previous total hip arthroplasty or arthrodesis of the affected hip joint(s) * patient is willing and able to complete scheduled follow-up evaluations as described in the informed consent * patient, or the patient's legally authorized representative, has participated in the informed consent process and is willing and able to sign an irb- approved informed consent exclusion criteria: * subjects will be excluded from this trial if they satisfy any of the following criteria as determined by the research staff or in the judgment of the treating physician: * patient has a total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc.) in the affected hip joint(s) * patient is septic or has an active infection * patient is uncooperative patient or is incapable of following directions * patient is diagnosed with osteoporosis * patient is diagnosed with a metabolic disorder which may impair bone formation * patient is diagnosed with osteomalacia * patient has distant foci of infections which may spread to the implant site
bp pal - hypertension chat bot pilot

Conditions: Hypertension

Summary: a 2-arm randomized pilot trial aimed at evaluating the effectiveness of a 6-month remote monitoring program for the management of hypertension (htn). 300 eligible patients will be randomized in a 1:1 ratio into two recruitment arms: a) control (usual care), or b) remote monitoring via automated messaging program. the target population are patients at the penn family medicine university city and westtown primary care practices with baseline poor blood pressure control as indicated by two blood pressures greater than 140/90 within the past twelve month including the most recent measurement and on at least one anti-hypertensive agent.

study design: pragmatic, non-blinded, randomized controlled trial. randomization and enrollment: * randomization will be at the patient level (stratified/balanced randomization by pcp) * enrollment will take place over short time period based off of lists of eligible patients pulled from the emr * lists of eligible patients sent to pcps with opportunity to opt patients out. patients will be contacted via text followed by phone call to introduce them to the program. we expect recruitment to take approximately 1 month to reach a target sample size of 300. the program itself will be 6 months from the date of randomization. total study duration should be approximately 7 months. data analyses will take an additional 3 months. the control group will receive usual care as determined by pcp (control arm will not receive bp cuffs).the intervention group will receive the bp cuff and weekly sms messages asking for the bp reading. the methods section below will outline the details for both groups.

Eligibility criteria:
inclusion criteria: * 1) two blood pressures \> 140/90 within the past 12 months, including the most recent measurement and 2) on at least one anti-hypertensive agent and 3) on htn registry and 4)on pcsl registry 5) are active patients at the penn family medicine university city, penn presby and westtown practices exclusion criteria: * any patients meeting the following criteria are excluded from the study: * on a pcsk9 inhibitor medication * pregnant or currently breastfeeding * have a significant disability or markedly shortened life expectancy (metastatic cancer, on hospice, esrd, dementia, end stage renal failure, congestive heart failure) * not fluent in english

Keywords: remote monitoring
early identification and treatment of rare cardiomyopathy cohorts

Conditions: Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Metabolic Cardiomyopathy; Restrictive Cardiomyopathy

Summary: this study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. the investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. in the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. the effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.

to answer what are the key clinical questions of patients with rare cardiomyopathies resulted in high risk of adverse outcomes and requiring intensified treatment, this study will systematically refine and expand the cohort. this study will combine multimodal imaging with clinical data, blood samples, myocardial tissue samples to retrospectively identify biomarkers associated with pathological changes in rare cardiomyopathies; thereby to integrate multi-dimensional data to develop and validate a prognostic risk assessment model and evaluate the effectiveness of treatments guided through prospective randomized controlled trials by this model. ultimately, this study aims to offer an integrated solution for the diagnosis and treatment of rare cardiomyopathies.

Eligibility criteria:
inclusion criteria: * age 18-75 years old. * patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments. * no history of structural heart disease, and the framingham score \&lt;5 (for patients with the framingham score ≥5, coronary artery disease will be excluded by coronary angiography/coronary ct/exercise platelet). * creatinine clearance ≥50ml/min (cockcroft-gault formula). * lvef ≥50% assessed by echocardiography. * qt interval \&lt; 470 ms. * providing written informed consent. exclusion criteria: * presence of acute/chronic renal impairment (gfr \&lt;50/ml/min/1.73m2). * history of cardiovascular disease such as confirmed coronary artery disease, valvular disease, cardiomyopathy, congenital heart disease, and heart failure. * presence of contraindications to cmr.

Keywords: rare cardiomyopathy, cardiac multimodal imaging, myocardial impairment
adv-tk improves outcome of recurrent high-grade glioma

Conditions: Malignant Glioma of Brain; Glioblastoma

Summary: malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy. the advantages of adv-tk gene therapy highlight its efficacy and safety for glioma patients. this clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant adv-tk, in combination with systemic intravenous gcv administration in patients with recurrent high-grade glioma.


Eligibility criteria:
inclusion criteria: * histologically confirmed who grades 3 to 4 malignant glioma * diagnosed recurrence or progression by clinical or radiological evidence * fit for intraarterial infusion and intravenous chemotherapy * adequate hepatic, renal, and hematologic function. * legal age ≥18 years * life expectancy ≥12 weeks * eastern cooperative oncology group performance (ecog) ≥2 * chemotherapy completion ≥4 weeks prior and recovery from drug induced toxicities. exclusion criteria: * active pregnancy * prior gene therapy * second primary tumor * gravidity, lactation, hypersensitivity to antiviral drugs, immunologic deficit, active uncontrolled infections * requiring treatment with warfarin or any other anticoagulants
assess efficacy and safety of azd6244 in combination with docetaxel in patients receiving second line non small cell lung cancer treatment.

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

Summary: the purpose of this study is to treat patients with locally advanced or metastatic nsclc with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose affects how their cancer responds. it will also help us to understand the tolerability profile of the different dosing regimens in these patients

a phase ii, double-blind, randomised, placebo-controlled study to assess the efficacy and safety of selumetinib (azd6244; arry-142886) (hyd-sulfate) in combination with docetaxel, compared with placebo in combination with docetaxel, in patients receiving second line treatment for locally advanced or metastatic non small cell lung cancer (stage iiib - iv)

Eligibility criteria:
inclusion criteria: * provision of signed, written and dated informed consent prior to any study specific procedures * male or female, aged 18 years or older * histological or cytological confirmation of locally advanced or metastatic nsclc (iiib-iv) * prospective confirmation of kras mutation negative status as determined via an az approved laboratory * failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy exclusion criteria: * mixed small cell and non-small cell lung cancer histology * received \>1 prior anti-cancer drug regimen for advanced or metastatic nsclc. patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible. * other concomitant anti-cancer therapy agents except steroids * prior treatment with a mek (mitogen-activated protein kinase) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable) * the last radiation therapy within 4 weeks prior to starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment.

Keywords: mitogen-activated protein kinase kinase inhibitor non small cell lung cancer metastatic second line treatment for non small cell lung cancer
use of fetoscopy in missed abortion

Conditions: Abortion, Missed

Summary: the purpose of this study is to evaluate the use of hysteroscopic embryoscopy or fetoscopy as a powerful diagnostic tool to provide better counseling for couples having experienced pregnancy loss.


Eligibility criteria:
inclusion criteria: * women diagnosed with missed abortion during the first trimester of pregnancy exclusion criteria: * women diagnosed with missed abortion after the first trimester of pregnancy * any contraindication for hysteroscopy
ethyl chloride spray to reduce pain from local anesthesia during mohs micrographic surgery

Conditions: Surgery

Summary: fear of needles is a well-documented issue that affects many patients. this fear may cause significant anxiety in various medical situations, including in the dermatology office 1. if not properly managed, needle phobia can persist, affecting a patient's experience during each visit. this effect may compound and lead to avoidance behaviors that can delay necessary treatments 2. this issue is particularly relevant in a mohs micrographic surgery (mms) clinic where each patient experiences several painful needle injections before the day is over. ethyl chloride is gaining popularity among dermatologists for its routine use in clinical practice due to its anesthetic and antiseptic properties, especially as a pre-injection agent. research indicates that cryotherapy or pre-cooling the skin before administering a local anesthetic may offer benefits over topical anesthetics, such as enhanced pain relief, quicker onset, and better patient compliance 3,4. however, to our knowledge, no studies have specifically examined the effectiveness of pre-cooling with ethyl chloride prior to mohs micrographic surgery. to address this gap, we're conducting a trial aimed at evaluating the impact of pre-cooling with ethyl chloride on pain perception in adult patients undergoing mohs micrographic surgery with local anesthetic injections. the trial is a single-center, split-body study. the split-body design will involve dividing the surgical site into two equal halves, with one half (right side relative to patient) designated as the treatment side (receiving ethyl chloride spray prior to lidocaine injection) and the other as the control side (no ethyl chloride spray prior to injection). during the procedure, the participant will be asked to rate the pain associated with the needle injection and the pain from infiltration of anesthetic from each side of the wound using the visual analog scale (vas) scoring system (1 = no pain, 10 = most amount of pain possible). the results of the study will help us better understand how to mitigate pain and anxiety for patients requiring mms.


Eligibility criteria:
inclusion criteria: * all patients scheduled for mms with dr. daniel eisen at uc davis health department of dermatology (3301 c st #1300-1400, sacramento, ca 95816) * pre-op tumor size at least 1.5 cm (measured on day of procedure) exclusion criteria: * skin disorders related to cold temperatures (i.e. cryoglobulinemia) * anxiolytic medication within past 4 hours * treatment sites around the eyes * pre-op tumor size smaller than 1.5 cm (measured on day of procedure)

Keywords: mohs micrographic surgery ethyl chloride spray
total post-thyroidectomy hypocalcemia after preoperative cholecalciferol supplementation

Conditions: Hypocalcemia

Summary: this prospective study evalue the inflence of pre operative vit d3 administration on post operative hypocalcemia in patients undergoing total thyroidectomy

thyroidectomy is a frequent procedure. this surgery is well known but not devoid of risks. the most common postoperative complication is transitory hypocalcemia. some studies have reported that preoperative vitamin d deficiency (vdd) is a risk factor for hypocalcemia after total thyroidectomy (tt) in patients with non toxic multinodular goiter or graves's disease. although the association between vvd and postoperative hypocalcemia in thyroid cancer patients undergoing tt plus central compartment neck dissection (ccnd) remains unclear. this prospective study evalue the inflence of pre operative vit d3 administration on post operative hypocalcemia in patients undergoing tt.

Eligibility criteria:
inclusion criteria: * patient ≥ 18 years old * patient shall be operated on for a total thyroidectomy in one time for any indication * written informed consent (ic) obtained * patients with affiliation to the social security system exclusion criteria: • medical history of : thyroid or parathyroid surgery hyperparathyroidism granulomatosis flare-up * hypocalcemia, hypercalcemia/ hypercalciuria, or symptom of hypocalcemia, hypercalcemia/ hypercalciuria, not due to thyroid pathologies * chronic kidney disease grade ≥4 * severe liver failure * 25ohd supplementation within last 3 months before surgery * malabsorption syndrome * known hypersensitivity to vitamin d * medical history of calcic lithiasis * pregnant women * vulnerable populations (guardianship or trusteeship) * allergies to one of the components of the fruit juice

Keywords: total thyroidectomy hypocalcemia cholecalciferol supplementation
phase iii study of bms-188667 (ctla4ig) in patients with rheumatoid arthritis who are currently failing anti-tnf therapy or who have failed anti-tnf therapy in the past.

Conditions: Rheumatoid Arthritis

Summary: the purpose of this clinical research study is to determine whether abatacept treatment on a background of disease modifying antirheumatic drugs (dmards) will relieve the symptoms of rheumatoid arthritis (ra) in participants who are currently receiving anti-tumor necrosis factor (tnf) therapy for at least 3 months and are not responding or have taken anti-tnf therapy in the last 3 months and did not respond. the safety of treatment with abatacept will also be evaluated. this study also has a 4.5-year long-term extension beginning 6 months after the start of the study.


Eligibility criteria:
eligibility criteria: * active rheumatoid arthritis currently failing anti-tnf therapy or have failed anti-tnf therapy in the past. exclusion criteria: * women who are pregnant or breast feeding * current symptoms of serious medical disease * history of cancer in last 5 years other than non-melanoma skin cancer * chronic serious infection * active tb requiring treatment in last 5 years * herpes zoster in last 2 months * any active viral infection including human immunodeficiency virus (hiv) * serious side effects associated with previous anti-tnf therapy